Key Takeaways
- Quality: Faeth carries no debt (debt-to-equity 0.00) and a current ratio of 19.69, but returns are deeply negative, with return on equity at -195.3% and a Quality score of 41 out of 100.
- Growth: With no product revenue, revenue and earnings growth figures are all N/A and the model assigns no Growth score, leaving pipeline progress as the only real growth lever.
- Opportunity: The stock trades near its two-year high of $40.05 at a price-to-book of 5.83, and the model’s Opportunity score is just 6 out of 100.
Faeth Therapeutics (FTH) is a clinical-stage healthcare company that the market has repriced dramatically, and this Faeth Therapeutics stock analysis starts with that gap: the shares change hands at $39.00, close to their two-year high of $40.05 and far above the two-year low of $5.78, even though the income statement still shows no product revenue. Based on Yahoo Finance data as of September 11, 2026, the company carries a market capitalisation of about $1.01 billion.
What Is Happening With the Stock Price
At $39.00 the stock sits at roughly 97% of its two-year range, firmly at the upper end. That price action reflects optimism about the drug pipeline rather than current financial results, because there are none to speak of yet. Sentiment can reverse quickly for names like this: with the stock priced for success, any clinical or regulatory disappointment would remove the main support under the valuation.
Quality: Is This a Financially Sound Business?
On reported profitability the picture is weak, as expected for a pre-commercial biotech. Gross margin and operating margin are both 0.0% because there is no revenue, return on assets is -20.8% and return on equity is -195.3%. Earnings per share are listed at -$60.86, an unusually large figure that is worth checking against the latest filing, since headline losses for recently listed biotechs are frequently amplified by non-cash accounting items rather than pure operating cash burn. The balance sheet is the bright spot: debt-to-equity is 0.00, and the current ratio of 19.69 and quick ratio of 19.46 point to a large cash cushion relative to near-term obligations. Free cash flow over the trailing twelve months is only about $1 million positive, so the company is close to cash-flow neutral for now, though that can change as trial spending scales. The model scores Quality at 41 out of 100, balancing the clean balance sheet against the poor returns.
Growth: Does This Company Have Real Upside?
There is no revenue base to measure in this Faeth Therapeutics stock analysis, so the five-year revenue CAGR, trailing-twelve-month revenue growth and earnings growth are all N/A, and the scoring model does not assign a Growth score. For a company at this stage, growth really means pipeline progression and future trial readouts, which these fundamentals do not capture. EV/Revenue is not available, and EV/EBITDA of -20.40 is negative simply because EBITDA is negative, not because the stock is cheap. Any upside case therefore rests on clinical execution that the current numbers cannot confirm.
Opportunity: Is Now a Good Time to Enter?
The model Opportunity score is 6 out of 100, one of the lowest readings it produces. The stock trades at the top of its two-year range, price-to-book is 5.83 despite deeply negative returns on equity, and there is no P/E because there are no earnings. The valuation and price-position signals all point the same way: an investor buying today is paying a full price near the highs for a business whose value depends on outcomes that have not yet happened. A more patient entry would wait for either a pullback or concrete pipeline milestones.
Faeth Therapeutics Stock Analysis: The Bottom Line
Because Quality, Growth and Opportunity do not all have adequate evidence – there is no revenue, no P/E and no Growth score – StreetBriefs’ quantitative model does not issue a Buy, Hold or Sell signal here, and the page shows an N/A rating rather than a rating by default. This Faeth Therapeutics stock analysis nets out as follows: the company is well funded and carries no debt, but it generates no revenue, posts steeply negative returns, and trades near its two-year high with a very low Opportunity score. The main risk is straightforward: clinical-stage biotechs face binary trial outcomes and ongoing dilution risk as they raise money to fund development, and a single failed study can reset the share price sharply. The offsetting possibility is that pipeline success could justify the current market value. On the fundamentals alone, Faeth is a speculative, event-driven name whose value hinges on clinical outcomes that today’s numbers cannot confirm.
Financial Metrics Summary
| Metric | Value |
|---|---|
| Price & Valuation | |
| Current Price | $39.00 |
| 2-Year Low | $5.78 |
| 2-Year High | $40.05 |
| Market Cap | $1.01B |
| Our Scores | |
| Quality Score | 41 / 100 |
| Opportunity Score | 6 / 100 |
| Profitability | |
| Earnings Per Share | -$60.86 |
| Return on Assets | -20.8% |
| Return on Equity | -195.3% |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Balance Sheet | |
| Debt-to-Equity | 0.00 |
| Current Ratio | 19.69 |
| Quick Ratio | 19.46 |
| Income & Dividends | |
| Payout Ratio | 0.0% |
Data as of September 11, 2026
Our Three-Pillar Assessment
| Quality |
41/100 |
| Growth |
N/A |
| Opportunity |
6/100 |
Quality measures business fundamentals: profitability, cash flow discipline, and balance sheet strength.
Growth captures revenue momentum, gross margin scalability, and the Rule of 40 efficiency test.
Opportunity signals entry timing: current valuation versus history and price position in the 2-year range.
Current price: $39.00 trading 3% below its 2-year high of $40.05.
This analysis is done using financial data from Yahoo Finance.
Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.
